Accès ouvert
2018
article
OpenAlex
JA Thompson, Cissy Kityo, David Dunn, Anne Hoppé et autres
BACKGROUND: Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment programs in low-income countries often delays detection of treatment failure. The impact of remaining on failing protease inhibitor (PI)-containing regimens is unclear. METHODS: We retrospectively tested VL in 2164 stored …
gb, Ouganda, ca, Zimbabwe, Malawi, es, sg
(code pays fourni par la source)
Accès ouvert
2017
article
OpenAlex
James Hakim, JA Thompson, Cissy Kityo, Anne Hoppé et autres
BACKGROUND: Millions of HIV-infected people worldwide receive antiretroviral therapy (ART) in programmes using WHO-recommended standardised regimens. Recent WHO guidelines recommend a boosted protease inhibitor plus raltegravir as an alternative second-line combination. We assessed whether this treatment option offers any advantage over the …
Zimbabwe, gb, Ouganda, Malawi, Kenya, Zambie, sg
(code pays fourni par la source)
Accès ouvert
2017
article
OpenAlex
Nicholas I. Paton, Leonard Bagenda, Joep J. van Oosterhout, Silvia Bertagnolio et autres
BACKGROUND: Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the …
sg, gb, Ouganda, Zimbabwe, Malawi, ch
(code pays fourni par la source)